Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Taiwan · Delayed Price · Currency is TWD 34.50
-0.15 (-0.43%)
Aug 19, 2026, 1:30 PM CST
TPE:1762 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 934.29 | 804.88 | 1,347 | 2,086 | 2,117 | 1,935 | |
Revenue Growth | -20.25% | -40.26% | -35.42% | -1.45% | 9.43% | 25.34% |
Cost of Revenue | 766.63 | 813.74 | 953.06 | 1,329 | 1,155 | 985.31 |
Gross Profit | 167.67 | -8.86 | 394.32 | 757.31 | 961.76 | 949.39 |
Selling, General & Admin | 135.03 | 142.33 | 182.14 | 233.8 | 271.78 | 239.89 |
Research & Development | 169.15 | 168.35 | 205.84 | 242.7 | 244.79 | 252.67 |
Operating Expenses | 304.18 | 310.67 | 387.98 | 476.5 | 498.23 | 510.91 |
Operating Income | -136.52 | -319.54 | 6.34 | 280.81 | 463.53 | 438.48 |
Interest Expense | -15.23 | -16.63 | -21.13 | -17.97 | -9.68 | -3.27 |
Interest & Investment Income | 2.79 | 3.78 | 8.65 | 8.25 | 4.51 | 0.18 |
Earnings From Equity Investments | 81.53 | 57.25 | 44.87 | 36.51 | 51.1 | 50.1 |
Currency Exchange Gain (Loss) | -5.37 | -5.37 | 23.64 | 6.88 | 56.82 | -9.59 |
Other Non Operating Income (Expenses) | 22.66 | 7.77 | 9.68 | 8.25 | 8.13 | 18.45 |
EBT Excluding Unusual Items | -50.15 | -272.73 | 72.04 | 322.72 | 574.41 | 494.34 |
Gain (Loss) on Sale of Investments | 16.92 | 16.92 | -15.42 | 10.77 | 9.59 | 3.27 |
Gain (Loss) on Sale of Assets | - | - | 0.61 | - | -0.7 | - |
Other Unusual Items | 0.13 | 0.13 | - | - | - | - |
Pretax Income | -33.1 | -255.68 | 57.22 | 333.49 | 583.31 | 497.61 |
Income Tax Expense | 18.61 | -11.83 | 4.19 | 68.58 | 117.17 | 96.56 |
Earnings From Continuing Operations | -51.71 | -243.85 | 53.03 | 264.91 | 466.14 | 401.05 |
Minority Interest in Earnings | - | - | - | - | -0.28 | -0.27 |
Net Income | -51.71 | -243.85 | 53.03 | 264.91 | 465.87 | 400.78 |
Net Income to Common | -51.71 | -243.85 | 53.03 | 264.91 | 465.87 | 400.78 |
Net Income Growth | - | - | -79.98% | -43.14% | 16.24% | -24.65% |
Shares Outstanding (Basic) | 55 | 56 | 56 | 78 | 78 | 78 |
Shares Outstanding (Diluted) | 55 | 56 | 56 | 78 | 79 | 78 |
Shares Change | 23.20% | -1.27% | -27.92% | -0.52% | 0.23% | -0.02% |
EPS (Basic) | -0.93 | -4.39 | 0.95 | 3.42 | 6.01 | 5.17 |
EPS (Diluted) | -0.93 | -4.39 | 0.94 | 3.39 | 5.93 | 5.12 |
EPS Growth | - | - | -72.27% | -42.83% | 15.82% | -24.59% |
Free Cash Flow | 249.63 | 81.24 | 364.57 | -516.27 | 359.12 | -184.18 |
Free Cash Flow Per Share | 4.50 | 1.46 | 6.48 | -6.61 | 4.58 | -2.35 |
Dividend Per Share | - | - | 0.190 | 0.800 | 1.300 | 1.300 |
Dividend Growth | - | - | -76.25% | -38.46% | 0% | -13.33% |
Gross Margin | 17.95% | -1.10% | 29.27% | 36.30% | 45.43% | 49.07% |
Operating Margin | -14.61% | -39.70% | 0.47% | 13.46% | 21.89% | 22.66% |
Profit Margin | -5.53% | -30.30% | 3.94% | 12.70% | 22.00% | 20.71% |
Free Cash Flow Margin | 26.72% | 10.09% | 27.06% | -24.74% | 16.96% | -9.52% |
EBITDA | 49.24 | -128.19 | 205.5 | 473.81 | 632.58 | 570.47 |
EBITDA Margin | 5.27% | -15.93% | 15.25% | 22.71% | 29.88% | 29.49% |
D&A For EBITDA | 185.76 | 191.35 | 199.16 | 193.01 | 169.05 | 131.99 |
EBIT | -136.52 | -319.54 | 6.34 | 280.81 | 463.53 | 438.48 |
EBIT Margin | -14.61% | -39.70% | 0.47% | 13.46% | 21.89% | 22.66% |
Effective Tax Rate | - | - | 7.32% | 20.56% | 20.09% | 19.41% |